Sanofi ADR [SNY] stock is trading at $48.20, down -1.17%. An important factor to consider is whether the stock is rising or falling in short-term value. The SNY shares have gain 4.37% over the last week, with a monthly amount drifted -3.37%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 24, February 2024, Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria. In a post published today on Yahoo Finance, .
From an analyst’s perspective:
Sanofi ADR [NASDAQ: SNY] stock has seen the most recent analyst activity on January 23, 2024, when Morgan Stanley initiated its Equal-Weight rating and assigned the stock a price target of $55. On December 05, 2023, downgrade downgraded it’s rating to Neutral. Stifel downgraded its rating to a Hold. Berenberg upgraded its rating to a Buy. In a note dated April 28, 2023, Deutsche Bank downgraded an Sell rating on this stock.
Sanofi ADR [SNY] stock has fluctuated between $42.63 and $57.82 over the past year. Currently, Wall Street analysts expect the stock to reach $48.07 within the next 12 months. Sanofi ADR [NASDAQ: SNY] shares were valued at $48.20 at the most recent close of the market. An investor can expect a potential drop of -0.27% based on the average SNY price forecast.
Analyzing the SNY fundamentals
Sanofi ADR [NASDAQ:SNY] reported sales of 46.56B for the trailing twelve months, which represents a drop of -13.36%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 47.96 points at the first support level, and at 47.71 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.67, and for the 2nd resistance point, it is at 49.13.
Sanofi ADR [SNY] reported earnings per share of $0.89 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.5/share, meaning a difference of -$0.61 and a surprise factor of -40.70%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $2.77 per share as compared to estimates of $2.27 per share, a difference of $0.5 representing a surprise of 22.00%.
Ratios To Look Out For
For context, Sanofi ADR’s Current Ratio is 1.27. On the other hand, the Quick Ratio is 0.87, and the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 2.60, the price to book ratio is 1.47 and price to earnings (TTM) ratio is 20.75.
